医药工业品集采持续推进，仿制药集采对行业的影响或已接近尾声。国家医保局目标是实现国家和省级集采药品数合计达450个，前七批国采已经近三百个品种，加上各省集采、省际联盟等，预计第八批国采后尚未集采的仿制药品种已所剩不多，集采对仿制药的冲击基本结束。我们当前看好医药板块如下主线：医疗服务修复，如金域医学、美年健康、爱尔眼科、通策医疗等；新基建带来的器械装备，如迈瑞医疗等；非新冠疫苗疫后恢复，如康泰生物、欧林生物等；中药消费品，如太极集团、昆药集团等；医药商业中具有特色业务的公司，如上海医药、百洋医药。
The collection of pharmaceutical products continues to advance, and the impact of generic drug collection on the industry may be nearing its end. The goal of the National Health Insurance Administration is to achieve a total of 450 drugs collected at the national and provincial levels. The first seven batches have already collected nearly 300 varieties. In addition to provincial collection, inter-provincial alliances, etc., it is expected that there are not many generic drug varieties left that have not yet been collected after the eighth batch of national procurement, and the impact of collection on generic drugs has basically come to an end. We are currently optimistic about the following main lines of the pharmaceutical sector: rehabilitation of medical services, such as Jinyu Medicine, American Health, Aier Ophthalmology, Tongce Medical, etc.; equipment brought about by new infrastructure, such as Mindray Medical, etc.; recovery from non-COVID-19 vaccines, such as Kangtai Biology, Olin Biology, etc.; consumer products of traditional Chinese medicine, such as Taiji Group, Kunming Pharmaceutical Group, etc.; companies with characteristic businesses in the pharmaceutical business, such as Shanghai Pharmaceutical and Baiyang Pharmaceutical.
